BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)

MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive... The post BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution) appeared first on Montreal Gazette .

Original source: Montreal Gazette